Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

ne million men in the United States have prostate cancer, with an estimated 186,320 new cases expected to be diagnosed in 2008, and approximately 28,660 men expected to die this year from the disease. Currently there are limited treatment options for men with advanced, metastatic prostate cancer.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. In clinical studies, patients typically received three doses of PROVENGE over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 The overall research objective ... sequencing trends and use. Most researchers outsource NGS ... to increase within the next 12 months. Data ... for purchasing sequencing instruments. Disease-related research is the ... RNA-Seq continues to surge, with half of the ...
(Date:9/30/2014)... Rainbow Scientific, Inc. (RSI), a North ... an online store to add customer convenience in ... and manufactured by Biological Industries, Inc. , Products ... Nutristem® serum-free, xeno-free reagents for human mesenchymal stem ... culture. , The online store also offers ...
(Date:9/30/2014)... Canada (PRWEB) September 30, 2014 Back in ... on 500 square feet. per employee, which included space for ... back then.” says Jeff Howell, partner at Nidea Corporate ... firm in Toronto. “By the year 2000, however, 250 ... now seeing that number come down to 175 to 225 ...
(Date:9/29/2014)... in Iraq and Afghanistan, more than 300,000 soldiers have ... caused by exposure to bomb blasts and in ... of traumatic brain injury can range from the mild, ... impairments in memory and cognition. , Since 2007, ... importance and complexity of this problem, and has made ...
Breaking Biology Technology:Global Next-generation Sequencing Trends 2Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4
... Va., Oct. 16 Varian Medical,Systems (NYSE: ... version of its market-leading,VariSeed(TM) brachytherapy seed planning ... allow greater visibility of the,treatment. "The ... the positions of,individual seeds in permanent seed ...
... Ranked 11th of the ,200 Best Small Companies In ... Inc.,(Nasdaq: ABAX ), a medical products company manufacturing ... chairman and chief executive officer, was named "Entrepreneur of,the ... issue. Also in that,issue, Abaxis was ranked eleventh of ...
... Novartis Takes Top Spot, Previously Held by GlaxoSmithKline ... 16 Thomson,Scientific, part of The Thomson Corporation ... of information solutions to the worldwide research and,business ... recent,quarterly review of scientific literature on drugs and ...
Cached Biology Technology:Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments 2Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments 3Abaxis CEO Clint Severson Named 'Entrepreneur of the Year' by Forbes Magazine 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 3
(Date:9/30/2014)... Journal of Medicine reports positive results of a ... the subset of lung cancer marked by rearrangement of ... patients with advanced non-small cell lung cancer testing positive ... percent, with 3 complete responses and 33 partial responses. ... the disease to resume its growth after being slowed ...
(Date:9/30/2014)... is available in German . ... the most expensive foods in the world. Because they grow ... But the distinctive smell of truffles is not only of ... under the direction of the Goethe University Frankfurt have discovered ... soil bacteria which are trapped inside truffle fruiting bodies. , ...
(Date:9/30/2014)... to using marijuana, new research, involving mice and published ... Journal of Leukocyte Biology , suggests that just ... should. That,s because a team of Italian scientists have ... long-term damage to the immune system. This damage may ... as multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis ...
Breaking Biology News(10 mins):NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2On the trail of the truffle flavor 2Adolescent exposure to thc may cause immune systems to go up in smoke 2
... An international team of researchers, including a University of ... giant cephalopod fossils discovered two years ago in England contain ... the melanin found in the ink sac of a modern-day ... May 21 edition of the journal Proceedings of the ...
... Stanford University School of Medicine, Stanford, California, has been honored ... her years of volunteer service to ASM. "For as long ... Baron has been the heart and soul of my profession," ... Development, North America, for bioMrieux, Inc., Durham, NC. ...
... by financial strategists to determine what shares to purchase to ... diversified portfolio of another kind -- land to be set ... Instead of plugging into the formula the data for ... Amy Ando and agricultural economist Mindy Mallory used the historical ...
Cached Biology News:Squid ink from Jurassic period identical to modern squid ink, U.Va. study shows 2Squid ink from Jurassic period identical to modern squid ink, U.Va. study shows 3The American Society for Microbiology honors Ellen Jo Baron 2The American Society for Microbiology honors Ellen Jo Baron 3Financial tool considered climate change uncertainty to select land for conservation 2Financial tool considered climate change uncertainty to select land for conservation 3
... is an aqueous-based mounting medium designed ... sections. Gel/Mount is especially recommended when ... or FluoroBlue. It can also be ... as fluorescein (FITC), Rhodamine (TMRITC) and ...
... - Fixation medium Reagent B - Permeabilisation ... fixing cells in suspension with Reagent A ... B. This procedure gives antibodies access to ... characteristics of the cells intact. Specific formulations ...
...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
Biology Products: